Polycystic Kidney Disease (PKD) Patients Needed for Research Study

The purpose of this study is to find a dose of hydralazine that would be best to treat patient with ADPKD.

The study is 8 weeks long and will take place at the University of Kansas Medical Center.

Study visits will occur every 2 weeks for a total of 5 visits. All participants will receive the study medication (hydralazine) for a duration of 6 weeks.

Blood and urnine specimens will be collected at every study visit. Standard medical assessments will occur throughout the study.

Eligibility Criteria

Inclusion Criteria:

- Adults between the age of 18-65 years of age

- Confirmed diagnosis of polycystic kidney disease (PKD)

Exclusion Criteria:

- Liver disease

- Other exclusions may apply    

 

Principal Investigator

Kerri McGreal, MD

Study Contact

Debbie Griffin, RN, dgriffin3@kumc.edu, 913-588-7691

Estimated Completion Date

Friday, February 15, 2019

ClinicalTrials.gov #

NCT03423810
04/26/2018